What is claimed is:

1. A compound of formula (I)



(I)

wherein

X is C or N ;

R^1 is hydrogen or lower alkyl;

R^2 is lower alkyl or $-(CH_2)_n-R^{2a}$;

R^{2a} is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, cycloalkyl, oxo, fluorinated lower alkyl or fluorinated lower alkoxy; a 5- or 6-membered monovalent heteroaromatic ring containing one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino or cycloalkyl; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

R^3 is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

R^4 is a 5- or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; naphthyl, which may optionally be mono-,

di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, nitro, halogenated lower alkyl, halogenated lower alkoxy, cyano, lower alkylsulfonyl or $-NR^7R^8$; or two adjacent substituents of the said phenyl residue together are $-O-(CH_2)_p-O-$ or $-(CH_2)_2-C(O)NH-$;
R^5 and R^6 are each independently hydrogen, lower alkyl, halogen or fluorinated methyl;
R^7 and R^8 are each independently hydrogen or lower alkyl; or R^7 and R^8 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated or aromatic heterocyclic ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur, said saturated or aromatic heterocyclic ring being optionally substituted by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino;
m is 0, 1 or 2;
n is 0 or 1;
p is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1, wherein R^1 is hydrogen.

3. The compound according to claim 1, wherein R^2 is lower alkyl or $-(CH_2)_n-R^{2a}$.

4. The compound according to claim 3, wherein R^2 is $-(CH_2)_n-R^{2a}$.

5. The compound according to claim 4, wherein R^{2a} is a cycloalkyl residues with three to six carbon atoms which may optionally be mono-, di-, tri- or tetra-substituted, independently, by lower alkyl and/or hydroxy.

6. The compound according to claim 4, wherein R^{2a} is a 5-membered heterocyclic ring containing one or two heteroatoms independently selected from nitrogen and oxygen, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by lower alkyl or by oxo.

7. the compound according to claim 4, wherein R^{2a} is a 5- or 6-membered heteroaromatic ring containing one, two or four heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-substituted by lower alkyl or by cycloalkyl.

8. The compound according to claim 4, wherein R^{2a} is a phenyl residue which is optionally mono- or di-substituted, independently, by lower alkoxy, halogen, halogenated lower alkyl, halogenated lower alkoxy or nitro.

9. The compound according to claim 1, wherein R^3 is an unsubstituted cycloalkyl residue with five or six carbon atoms.

10. The compound according to claim 1, wherein R^3 is a phenyl residue which is optionally mono- or di-substituted, independently, by lower alkoxy, halogen, halogenated lower alkyl, halogenated lower alkoxy or nitro.

11. The compound according to claim 1, wherein R^4 is a 6-membered heteroaromatic ring containing one or two nitrogen atoms, said heteroaromatic ring being optionally mono-substituted by lower alkyl.

12. The compound according to claim 1, wherein R^4 is phenyl optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, nitro, halogenated lower alkyl, halogenated lower alkoxy, cyano, lower alkylsulfonyl, or by a residue $-NR^7R^8$.

13. The compound according to claim 1, wherein two adjacent substituents of a phenyl residue R^4 together are $-O-(CH_2)_p-O-$ or $-(CH_2)_2-C(O)NH-$, and p is 2 or 3.

14. The compound according to claim 13, wherein both R^7 and R^8 are methyl or both R^7 and R^8 are ethyl.

15. The compound according to claim 13, wherein R^7 and R^8 together with the nitrogen atom to which they are attached form a 5-membered, saturated heterocyclic ring optionally

containing one further heteroatom independently selected from nitrogen and oxygen, said saturated or aromatic heterocyclic ring being optionally mono-substituted by lower alkyl.

16. The compound according to claim 1, wherein X is C.

17. The compound according to claim 1, wherein X is N.

18. The compound according to claim 1, selected from the group consisting of:
1-Cyclohexylmethyl-5-(4-methoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(3-methoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-2-methyl-5-(4-trifluoromethyl-phenyl)-1H-pyrrole-3-carboxylic acid butylamide,
5-(4-Chloro-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-2-methyl-5-p-tolyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(2-methoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(4-fluoro-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(2,4-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
5-(4-Bromo-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, and
5-(3-Cyano-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, or a pharmaceutically acceptable salt thereof.

19. The compound according to claim 1, selected from the group consisting of:
1-Cyclohexylmethyl-5-(2,4-dimethyl-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(4-difluoromethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-2-methyl-5-(4-pyrrolidin-1-yl-phenyl)-1H-pyrrole-3-carboxylic acid butylamide,

1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(3,4-difluoro-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
5-(3-Chloro-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-2-methyl-5-(4-trifluoromethoxy-phenyl)-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(3,4-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
5-(2-Chloro-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, and
1-Cyclohexylmethyl-2-methyl-5-(4-nitro-phenyl)-1H-pyrrole-3-carboxylic acid butylamide, or a pharmaceutically acceptable salt thereof.

20. The compound according to claim 1, selected from the group consisting of:
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclopentylamide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclobutylamide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylamide,
1-Cyclohexylmethyl-5-(2,5-difluoro-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(4-hydroxy-3-methoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(3-fluoro-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
5-Benzo[1,3]dioxol-5-yl-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-5-(2,5-dichloro-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid butylamide, and

5-(3,5-Bis-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid butylamide,
or a pharmaceutically acceptable salt thereof.

21. The compound according to claim 1, selected from the group consisting of:
5-(3,5-Bis-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,
1-Cyclohexylmethyl-2-methyl-5-(4-pyrrolidin-1-yl-phenyl)-1H-pyrrole-3-carboxylic acid cyclohexylamide,
(R)-1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,
5-(3,5-Bis-trifluoromethyl-phenyl)-1-(4-methoxy-benzyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
1-Cyclohexylmethyl-2-methyl-5-pyridin-2-yl-1H-pyrrole-3-carboxylic acid butylamide,
1-Cyclohexylmethyl-2-(2-methoxy-phenyl)-5-methyl-1H-imidazole-4-carboxylic acid butylamide, and
1-Cyclohexylmethyl-2-(2-methoxy-phenyl)-5-methyl-1H-imidazole-4-carboxylic acid piperidin-1-ylamide,
or a pharmaceutically acceptable salt thereof.

22. The compound according to claim 1, selected from the group consisting of:
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclopropylmethyl-amide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (furan-2-ylmethyl)-amide,
1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid (3-methyl-thiophen-2-ylmethyl)-amide,
(S)-1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid sec-butylamide,
5-(5-Chloro-2-methoxy-4-methyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,

5-(3,5-Bis-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
1-Cyclohexylmethyl-5-(5-fluoro-2-methoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
5-(5-Chloro-2-methoxy-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
5-(5-Chloro-2-methoxy-4-methyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide and
5-(2-Chloro-5-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid ((1RS,2RS)-2-hydroxy-cyclohexyl)-amide
or a pharmaceutically acceptable salt thereof.

23. The compound according to claim 1, selected from the group consisting of:
5-(2-Chloro-5-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid ((1R,2R)-2-hydroxy-cyclohexyl)-amide,
5-(2,5-Bis-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
5-(2-Chloro-5-trifluoromethyl-phenyl)-1-cyclohexylmethyl-2-methyl-1H-pyrrole-3-carboxylic acid piperidin-1-ylamide,
5-(2-Fluoro-5-trifluoromethyl-phenyl)-1-((1SR,2RS)-2-hydroxy-cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,
5-(2-Fluoro-5-trifluoromethyl-phenyl)-1-((1RS,2RS)-2-hydroxy-cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide,
5-(2-Fluoro-5-trifluoromethyl-phenyl)-1-(1RS,2RS)-2-hydroxy-cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ((1R,2R)-2-hydroxy-cyclohexyl)-amide,
5-(2,5-Bis-trifluoromethyl-phenyl)-1-(2-cyclopropyl-ethyl)-2-methyl-1H-pyrrole-3-carboxylic acid ((1R,2R)-2-hydroxy-cyclohexyl)-amide,
5-(2-Chloro-5-trifluoromethyl-phenyl)-1-((1RS,2RS)-2-hydroxy-cyclohexylmethyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide, and
1-Cyclohexylmethyl-2-methyl-5-(2-methyl-5-trifluoromethyl-phenyl)-1H-pyrrole-3-carboxylic acid ((1R,2R)-2-hydroxy-cyclohexyl)-amide
or a pharmaceutically acceptable salt thereof.

24. A process for the manufacture of compounds of formula (I) as defined in claim 1, which process comprises:

(a) where X is C, reaction of an enamine of formula A:



wherein R^1, R^2, R^3, R^6 and m are as defined claim 1;

with an alfa-bromoketone of formula B:



wherein R^4 and R^5 are as defined claim 1.

25. The process according to claim 24, further comprising converting the resulting compound of formula I into a pharmaceutically acceptable salt thereof.

26. A process for the manufacture of compounds of formula (I) as defined in claim 1, which process comprises:

(a) where X is N, alkylation of an imidazole of formula F:



wherein R^1, R^2, R^4 and R^6 are as defined claim 1;

with an alkyl bromide of formula G:

$$R^3(CH_2)_m\text{-}Br$$

wherein R^3 and m are as defined claim 1.

27. The process according to claim 26, further comprising converting the resulting compound of formula I into a pharmaceutically acceptable salt thereof.

28. A process for the manufacture of compounds of formula (I) as defined in claim 1, which process comprises:

(a) where X is C, reaction of a carboxylic acid of formula N



wherein R^3, R^4, R^5,R^6 and m are as defined claim 1;

with an amine of formula J



wherein R^1 and R^2 are as defined claim 1.

29. The process according to claim 28, further comprising converting the resulting compound of formula I into a pharmaceutically acceptable salt thereof.

30. A compound manufactured by a process according to claim 24.

31. A compound manufactured by a process according to claim 26.

32. A compound manufactured by a process according to claim 28.

33. A pharmaceutical compositions comprising a compound of formula (I)



(I)

wherein

X is C or N ;

R^1 is hydrogen or lower alkyl;

R^2 is lower alkyl or $-(CH_2)_n-R^{2a}$;

R^{2a} is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, cycloalkyl, oxo, fluorinated lower alkyl or fluorinated lower alkoxy; a 5- or 6-membered monovalent heteroaromatic ring containing one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino or cycloalkyl; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

R^3 is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;

R^4 is a 5- or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; naphthyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, nitro, halogenated lower alkyl, halogenated lower alkoxy, cyano, lower alkylsulfonyl or $-NR^7R^8$; or two adjacent substituents of the said phenyl residue together are $-O-(CH_2)_p-O-$ or $-(CH_2)_2-C(O)NH-$;

R^5 and R^6 are each independently hydrogen, lower alkyl, halogen or fluorinated methyl;

R^7 and R^8 are each independently hydrogen or lower alkyl; or R^7 and R^8 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated or aromatic

heterocyclic ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur, said saturated or aromatic heterocyclic ring being optionally substituted by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino;

m is 1 or 2;

n is 0 or 1;

p is 1, 2 or 3;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable carrier and/or adjuvant.

34. A method for the treatment and/or prophylaxis of a disease associated with the modulation of the CB1 receptors which method comprises administering, to a patient in need thereof, a therapeutically effective amount of a compound of formula (I)



(I)

wherein

X is C or N ;

R^1 is hydrogen or lower alkyl;

R^2 is lower alkyl or $-(CH_2)_n-R^{2a}$;

R^{2a} is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; a 5-or 6-membered monovalent saturated heterocyclic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heterocyclic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, amino, lower alkylamino, cycloalkyl, oxo, fluorinated lower alkyl or fluorinated lower alkoxy; a 5- or 6-membered monovalent heteroaromatic ring containing one to four heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino or cycloalkyl; or phenyl, which may optionally be mono-,

di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;
R^3 is cycloalkyl, optionally mono-, di-, tri- or tetra-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, fluorinated lower alkyl or fluorinated lower alkoxy; or phenyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro;
R^4 is a 5- or 6-membered monovalent heteroaromatic ring containing one to three heteroatoms independently selected from nitrogen, oxygen and sulfur, said heteroaromatic ring being optionally mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, amino, lower alkylamino; naphthyl, which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, lower alkylamino, halogenated lower alkyl, halogenated lower alkoxy or nitro; or phenyl which may optionally be mono-, di- or tri-substituted, independently, by hydroxy, lower alkyl, lower alkoxy, halogen, nitro, halogenated lower alkyl, halogenated lower alkoxy, cyano, lower alkylsulfonyl or $-NR^7R^8$; or two adjacent substituents of the said phenyl residue together are $-O-(CH_2)_p-O-$ or $-(CH_2)_2-C(O)NH-$;
R^5 and R^6 are each independently hydrogen, lower alkyl, halogen or fluorinated methyl;
R^7 and R^8 are each independently hydrogen or lower alkyl; or R^7 and R^8 together with the nitrogen atom to which they are attached form a 5- or 6-membered saturated or aromatic heterocyclic ring optionally containing one or two further heteroatoms independently selected from nitrogen, oxygen and sulfur, said saturated or aromatic heterocyclic ring being optionally substituted by hydroxy, lower alkyl, lower alkoxy, halogen, amino or lower alkylamino;
m is 1 or 2;
n is 0 or 1;
p is 1, 2 or 3;
or a pharmaceutically acceptable salt thereof.

35. The method according to claim 34, wherein wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of psychic disorders, anxiety, psychosis, schizophrenia, depression, abuse of psychotropes, abuse and/or dependence of a substance, alcohol dependency, nicotine dependency, neuropathies, migraine, stress, epilepsy, dyskinesias, Parkinson's disease, amnesia, cognitive disorders, senile dementia,

Alzheimer's disease, eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), gastrointestinal diseases, vomiting, diarrhea, urinary disorders, cardiovascular disorders, infertility disorders, inflammations, infections, cancer, neuroinflammation, in particular in atherosclerosis, or the Guillain-Barré syndrome, viral encephalitis, cerebral vascular incidents and cranial trauma.

36. The method according to claim 34, wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), neuroinflammation, diarrhea, abuse and/or dependence of a substance, alcohol dependency, nicotine dependency.

37. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is selected from the group consisting of eating disorders, obesity, diabetes type II or non insulin dependent diabetes (NIDD), abuse and/or dependence of a substance, alcohol dependency and nicotine dependency.

38. The method according to claim 35, wherein the disease associated with the modulation of the CB1 receptor is obesity.